[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"sympathetic-nerve-activity\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:sympathetic-nerve-activity":32},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":5},"100434215","phase-1-mitigating-the-pro-inflammatory-phenotype-of-obesity-100434215",false,"NCT04934228","Mitigating the Pro-inflammatory Phenotype of Obesity","MAPLE","Inclusion Criteria:\n\n* Male or Female, age 18-79\n* Obese: BMI \\> 30 m\u002Fkg2\n* Hypertensive: blood pressure \\>130\u002F80\n* Elevated insulin resistance (HOMA-IR \\> 2.5)\n* Waist circ: \\>102 cm (men) and \\>88 cm (women)\n* Fasting glucose \\\u003C 126 mg\u002FdL\n* Fasting triglycerides \\\u003C 250 mg\u002FdL\n* HbA1c \\\u003C 6.5%\n* Willing to visit research lab (Fairway CTSU)\n* Willing to undergo a blood draw\n* Able to provide written informed consent\n\nExclusion Criteria:\n\n* Current use of clonidine or beta-blockers\n* Current smoker or History of smoking in the past 3 months.\n* Hyperlipidemia: Fasting triglycerides \\> 250 mg\u002FdL\n* Currently taking hypertension medication\n* History of heart disease (e.g., myocardial infarction, stent, byass, heart attack, stroke, heart failure, valvular heart disease, cardiomyopathy)\n* History of neurological disorders\n* History of transplant\n* Actively participating in other studies, except for a registry study.","ALL","18 Years","79 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","The purpose of this study is to examine the hypothesize that 4 weeks of sympathetic nerve activity (SNA) inhibition (oral clonidine) will cause a significant reduction in circulating blood concentrations and endothelial cell expression of inflammatory markers (e.g., TNF-α, IL-6).\n\nOur study is a prospective study using a randomized, double-blinded design to test 4 weeks of SNA blockade (oral clonidine) compared with a BP-lowering control condition (diuretic, hydrochlorothiazide) or a placebo.",[27,28,29,30,31,32],"Blood Pressure","Diabetes","Obesity","Insulin Resistance","Diuretics Drug Reactions","Sympathetic Nerve Activity","RECRUITING","2025-06-04",{"date":36,"type":37},"2025-06-05","ACTUAL",{"date":39,"type":37},"2021-07-01",{"date":41,"type":21},"2027-08-01",{"name":43,"class":44},"University of Kansas Medical Center","OTHER"]